(Press-News.org) A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.
The study follows previous discovery by the same group showing that a protein called apolipoprotein A-I (apoA-I) in patients may be used as a biomarker to diagnose early stage ovarian cancer, when it typically is asymptomatic and is much easier to treat. These earlier findings could be vital to improving early detection, as more than 85 percent of ovarian cancer cases present in the advanced stages, when the cancer has already spread and patients are more likely to have a recurrence after treatment, said Dr. Robin Farias-Eisner, chief of gynecologic oncology and co-senior author of the study with Dr. Srinu Reddy, a professor of medicine.
"The vast majority of ovarian cancer patients are diagnosed with advanced disease and the vast majority of those, after surgery and chemotherapy, will eventually become resistant to standard therapy," Farias-Eisner said. "That's the reason these patients die. Now, with this peptide as a potential therapy, and if successful in clinical trials, we may have a novel effective therapy for recurrent, chemotherapy-resistant ovarian cancer, without compromising the quality of life during treatment."
The study was published Nov. 1, 2010 in the early online edition of the peer-reviewed journal Proceedings of the National Academy of Sciences.
In their previous work, Farias-Eisner, Reddy and their research teams identified three novel biomarkers that they used to diagnose early stage ovarian cancer. In September 2009, the U.S. Food and Drug Administration cleared the first laboratory test that can indicate the likelihood of ovarian cancer, OVA1TM Test, which includes the three biomarkers identified and validated by Farias-Eisner, Reddy and their research teams.
They observed that one of the markers, apoA-I, was decreased in patients with early stage disease. They wondered why the protein was decreased and set out to uncover the answer. They speculated that the protein might be protective, and may be preventing disease progression.
The protein, apoA-I, is the major component of HDL, the good cholesterol, and plays an important role in reverse cholesterol transport by extracting cholesterol and lipids from cells and transferring it to the liver for extraction. The protein also has anti-inflammatory and antioxidant properties. Because lipid transport, inflammation and oxidative stress are associated with the development and progression of cancer, Farias-Eisner and Reddy hypothesized that the reduced levels of apoA-I in ovarian cancer patients may be causal in disease progression.
Mice that were engineered to have many copies of human apoA-I gene showed very little cancer development when induced with ovarian cancer, while the mice without the extra copies of apoA-I showed much more disease. The mice with extra copies of the apoA-I gene also lived 30 to 50 percent longer than those who didn't receive it.
Farias-Eisner and Reddy wanted to treat the mice that had more cancer with the protein apoA-I, but it was too large to conveniently administer, having 243 amino acids. The researchers then turned to apoA-I mimetic peptides - only 18 amino acids in length - that are being tested for cardiovascular diseases. That project had been ongoing for a number of years at UCLA, said Reddy, who is also a part of the cardiovascular research team led by Dr. Alan M. Fogelman, executive chair of the Department of Medicine.
"The smaller peptides mimic the larger apoA-I protein and provided us with agents we could give to the mouse to see if it was effective in fighting ovarian cancer," said Reddy. "One of the peptides was being tested as an experimental therapy for atherosclerosis, so we already have some information on how it's being tolerated in humans, which would be vital information to have if we progressed to human studies in ovarian cancer."
The peptide, thus far, has caused little to no side effects in atherosclerosis patients, Reddy said, a hopeful sign that it might be well tolerated in ovarian cancer patients.
The mice that were given the peptide by injection had about 60 percent less cancer than the mice that did not receive the peptide, Farias-Eisner said. The peptide also was given in drinking water or in mouse food and proved to be as effective when administered that way.
"It was an exciting result," Farias-Eisner said. "It looked like we had something that could be ingested or injected that might be very effective against ovarian cancer progression."
Farias-Eisner said the peptide avidly binds oxidized lipids, one of which is known to stimulate cancer cells to survive and multiply. In the mouse studies, the mice that received peptide had significantly lower levels of this cancer promoting lipid.
An early phase clinical trial is being planned testing the peptide in patients with aggressive ovarian cancers that are resistant to chemotherapy, a group of patients whose median survival is just 40 months. Farias-Eisner hopes the study will be started and completed within two years.
INFORMATION:
UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2010, the Jonsson Cancer Center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 10 of the last 11 years. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.
Peptide being tested to treat atherosclerosis inhibits ovarian cancer growth
2010-11-02
ELSE PRESS RELEASES FROM THIS DATE:
Earth's first great predator wasn't
2010-11-02
Boulder, CO, USA - The meters-long, carnivorous "shrimp" from hell that once ruled the seas of Earth a half billion years ago may have been a real softy, it turns out. A new 3-D modeling of the mouth parts of the Anomalocaris, along with evidence that these parts were not hard like teeth, but flexible, shows that the famed predator could not have been munching on the hard shells of trilobites and other such creatures of the early seas.
What's more, there is no evidence from fossilized stomach contents or feces that Anomalocaris' ate anything hard enough to leave a fossilized ...
How lead gets into urban vegetable gardens
2010-11-02
Boulder, CO, USA - One common mitigation approach is to build a raised bed and fill it with freshly composted, low-lead soil from elsewhere, right? Maybe not, according to researchers studying the mysterious case of the lead contamination found within raised beds in community gardens in the Boston communities of Roxbury and Dorchester.
"Raised beds are surrounded by a sea of contaminated soil," said Daniel Brabander of Wellesley College. Brabander, his students and colleagues have been studying the lead in 144 backyard gardens in coordination with The Food Project, an ...
Morrison Natural History Museum discovers baby sauropod tracks
2010-11-02
Morrison, CO, USA–Staff at the Morrison Natural History Museum have again discovered infant dinosaur footprints in the foothills west of Denver, Colorado, near the town of Morrison. Dating from the Late Jurassic, some 148 million years ago, these tracks were made before the Rocky Mountains rose, when Morrison was a broad savanna full of dinosaurs.
The fossil tracks represent infant sauropods, according to discoverer Matthew Mossbrucker, the museum's director. Sauropods are giant, herbivorous long-necked dinosaurs, sometimes known as "brontosaurs." The sauropod Apatosaurus ...
Scarcity of new energy minerals will trigger trade wars
2010-11-02
Boulder, CO, USA - It's not hard to argue in favor of alternatives to fossil fuels these days, but one popular argument – domestic energy security – may be standing on very shaky legs. A lot of rare metals are needed to make photovoltaic panels, rare earth magnets for wind generators, fuel cells and high-capacity batteries for hybrid and electric vehicles. But most industrialized nations, including the United States, are almost entirely dependent on foreign sources for those metals. The only way this is going to change is if there is more domestic exploration and mining. ...
UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater
2010-11-02
The November 2010 issue of "Environmental Pollution" details successful experiments at the University of Cincinnati wherein rabbit's food resulted in the abiotic (non-biological) transformation and absorption of four different types of estrogen, reducing the levels of these estrogen hormones by more than 80 percent in wastewater.
The research has practical implications since it could point to inexpensive treatment technologies and materials for reducing estrogens in wastewater.
Currently, estrogen in wastewater represents a major conduit for the entry of the hormone, ...
Antibiotics have long-term impacts on gut flora
2010-11-02
Short courses of antibiotics can leave normal gut bacteria harbouring antibiotic resistance genes for up to two years after treatment, say scientists writing in the latest issue of Microbiology, published on 3 November.
The researchers believe that this reservoir increases the chances of resistance genes being surrendered to pathogenic bacteria, aiding their survival and suggesting that the long-term effects of antibiotic therapy are more significant than previously thought.
Antibiotics that are prescribed to treat pathogenic bacteria also have an impact on the normal ...
Childhood stroke study identifies the contraceptive pill and smoking as risk factors
2010-11-02
Researchers are calling for clear guidelines on childhood stroke after a study, published in the November issue of Acta Paediatrica, found wide variations in time lag to diagnosis, investigation and treatment.
They are also keen to see the development of appropriate rehabilitation services, after a follow-up study found that 85% of the children who survived a stroke had neurological dysfunction or limitations.
Dr Sten Christerson studied the records of all children who had experienced their first stroke over a seven-year period in the Uppsala-Orebro Health Care Region, ...
Arthritis drugs could help prevent memory loss after surgery, study suggests
2010-11-02
Anti-inflammatory drugs currently used to treat diseases such as rheumatoid arthritis may also help prevent cognitive problems after surgery, according to a new study by researchers at Imperial College London and University of California, San Francisco (UCSF).
The research also reveals for the first time that a specific inflammatory response in the brain may explain why many patients experience memory loss or other forms of cognitive dysfunction after surgery or critical illness.
The findings, from research in mouse models, could lead to human clinical trials within ...
Quantum computing with braids in flatland
2010-11-02
When confined to a 2-dimensional sheet, some exotic particle-like structures known as anyons appear to entwine in ways that could lead to robust quantum computing schemes, according to research appearing in the November 1 issue of the journal Physical Review B. The physicists at Bell Laboratories who performed the research are hopeful the anyons can be induced to follow paths that twist into braids that would be much more resistant to disturbances that corrupt data and calculations in quantum computers relying on individual particles.
The anyons the researchers believe ...
Virginia Tech computer scientist, student design award winning software to combat hacking
2010-11-02
One of the serious threats to a user's computer is a software program that might cause unwanted keystroke sequences to occur in order to hack someone's identity. This form of an attack is increasing, infecting enterprise and personal computers, and caused by "organized malicious botnets," said Daphne Yao, assistant professor of computer science at Virginia Tech (http://www.cs.vt.edu/user/115).
To combat the "spoofing attacks," Yao and her former student, Deian Stefan, now a graduate student in the computer science department at Stanford University, developed an authentication ...